A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Lymphomas Bookmark and Share

Lymphomas

City of Hope is one of the largest and most successful treatment centers in the country for patients with lymphoma. Because of our vast experience in treating patients with this type of cancer, our specialists lead the field of hematopoietic cell transplantation (HCT) with excellent outcomes. Since 1976, City of Hope has performed more than 11,000 transplants for patients from virtually every state and around the world. 
 
As one of a select number of institutes to attain the elite designation of Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment.  We collaborate with scientists at City of Hope and other nationally recognized research institutions to develop tomorrow’s breakthrough treatments today. With our extensive program of clinical trials, newly diagnosed or relapsed lymphoma patients can find a clinical trial targeted to their condition. 
 

A Commitment to Create

At City of Hope, we also create new treatments for lymphoma. We pioneered “mini” hematopoietic cell transplants that allow for transplantation in older lymphoma patients.  We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing clinical trials, our physicians and researchers continue to lead the way in improving outcomes in lymphoma patients.   
 
City of Hope has pioneered innovative transplant regimens that have improved the cure rate for patients with Hodgkin lymphoma, non-Hodgkin lymphoma and other hematologic disorders. 
 
City of Hope combines both transplant and non-transplant therapies in the treatment of lymphomas. Delivered by a multidisciplinary treatment team that works closely and collaboratively, treatment planning begins upon the very first visit. Because of the close coordination among our specialists, there is a smoother transition and expedited treatment for those patients who ultimately need a stem cell transplant. In addition, lymphoma patients are at risk of developing myelodysplasia. Our researchers have developed biomarkers to determine who may be at risk of developing this complex disease. For more information about treatment approaches including chemotherapy, immunotherapy, radioimmunotherapy, adoptive T cell therapy, stem cell transplantation, click here.
 
City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. The studies are aimed at creating lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.
 
To learn more about our lymphoma program, diagnosis and treatment of lymphomas, click here.
 
 
A Leader in Lymphoma Research 

City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute and many other research-based organizations. We collaborate with other leading research institutions to develop tomorrow’s breakthroughs today. With our extensive program of clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
Our Developmental Therapeutics Program has an active portfolio of trials for patients with recurrent lymphoma, including trials of new chemotherapy and immunotherapy drugs. We are also actively involved in survivorship research.

City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) program is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. It aims to develop novel approaches derived from molecular and immunologic studies of T cell and antibody-based therapies. Its goal is also to create lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.

To learn more about our clinical trials program and to find trials for lymphoma, click here.
 

Lymphomas

Lymphomas

City of Hope is one of the largest and most successful treatment centers in the country for patients with lymphoma. Because of our vast experience in treating patients with this type of cancer, our specialists lead the field of hematopoietic cell transplantation (HCT) with excellent outcomes. Since 1976, City of Hope has performed more than 11,000 transplants for patients from virtually every state and around the world. 
 
As one of a select number of institutes to attain the elite designation of Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment.  We collaborate with scientists at City of Hope and other nationally recognized research institutions to develop tomorrow’s breakthrough treatments today. With our extensive program of clinical trials, newly diagnosed or relapsed lymphoma patients can find a clinical trial targeted to their condition. 
 

A Commitment to Create

At City of Hope, we also create new treatments for lymphoma. We pioneered “mini” hematopoietic cell transplants that allow for transplantation in older lymphoma patients.  We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing clinical trials, our physicians and researchers continue to lead the way in improving outcomes in lymphoma patients.   
 
City of Hope has pioneered innovative transplant regimens that have improved the cure rate for patients with Hodgkin lymphoma, non-Hodgkin lymphoma and other hematologic disorders. 
 
City of Hope combines both transplant and non-transplant therapies in the treatment of lymphomas. Delivered by a multidisciplinary treatment team that works closely and collaboratively, treatment planning begins upon the very first visit. Because of the close coordination among our specialists, there is a smoother transition and expedited treatment for those patients who ultimately need a stem cell transplant. In addition, lymphoma patients are at risk of developing myelodysplasia. Our researchers have developed biomarkers to determine who may be at risk of developing this complex disease. For more information about treatment approaches including chemotherapy, immunotherapy, radioimmunotherapy, adoptive T cell therapy, stem cell transplantation, click here.
 
City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. The studies are aimed at creating lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.
 
To learn more about our lymphoma program, diagnosis and treatment of lymphomas, click here.
 
 
A Leader in Lymphoma Research 

City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute and many other research-based organizations. We collaborate with other leading research institutions to develop tomorrow’s breakthroughs today. With our extensive program of clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
Our Developmental Therapeutics Program has an active portfolio of trials for patients with recurrent lymphoma, including trials of new chemotherapy and immunotherapy drugs. We are also actively involved in survivorship research.

City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) program is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. It aims to develop novel approaches derived from molecular and immunologic studies of T cell and antibody-based therapies. Its goal is also to create lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.

To learn more about our clinical trials program and to find trials for lymphoma, click here.
 
Quick Links
 
Why City of Hope
Stephen J. Forman, Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, talks about why City of Hope is a special place for cancer treatment.
 
Hematologic Cancers Support Groups
The focus of the Division of Hematopoietic Stem Cell and Leukemia Research is to improve the understanding of leukemia stem cells in order to develop cures for leukemia and other hematologic malignancies.
NEWS & UPDATES
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...
  • Cancer treatment can take a toll on the mouth, even if a patient’s cancer has nothing to do with the head or throat, leading to a dry mouth, or a very sore mouth, and making it difficult to swallow or eat. Here’s some advice from the National Cancer Institute (NCI)  on how to ease cancer-related dis...
  • Radiation oncology is one of the three main specialties involved in the successful treatment of cancer, along with surgical oncology and medical oncology. Experts in this field, known as radiation oncologists, advise patients as to whether radiation therapy will be useful for their cancer – and how it can best ...
  • There’s more to cancer care than simply helping patients survive. There’s more to cancer treatment than simple survival. Constant pain should not be part of conquering cancer,  insists Betty Ferrell, Ph.D., R.N., director of nursing research and education at City of Hope. She wants patients and caregivers...
  • Even its name is daunting. Systemic mastocytosis is a fatal disease of the blood with no known cure. But a new study suggests a bone marrow transplant may be the answer for some patients. While rare, systemic mastocytosis is resistant to treatment with drugs and, when aggressive, can be fatal within four years ...
  • Could what you eat affect the health of your chromosomes? The short answer is, “Yes.” Researchers led by Dustin Schones, Ph.D., assistant professor in the Department of Cancer Biology, and Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research and the National Business Products Industry ...
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...
  • Brain tumor removal would seem to be the obvious course of action in the wake of a brain tumor diagnosis, but that’s not always the case. Some tumors are too difficult for many surgeons to reach or too close to areas that control vital functions. Removing them just proves too risky. A new device being con...